Study guide

6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity

Key Takeaways Explain This Topic AI

The Gell and Coombs classification partitions immune hypersensitivity into four distinct mechanisms: Type I (IgE-mediated immediate mast cell degranulation), Type II (IgG/IgM-mediated cytotoxic or receptor-altering), Type III (soluble immune complex microvascular deposition), and Type IV (delayed-type T-cell and macrophage mediated).

Local anesthetic adverse reactions must distinguish true IgE allergy (rare, primarily due to ester metabolism to para-aminobenzoic acid [PABA] or methylparaben preservatives in multi-dose amide vials) from vasovagal syncope or systemic toxic epinephrine reactions.

Primary immunodeficiencies include Severe Combined Immunodeficiency (SCID; X-linked IL2RG or autosomal recessive ADA deficiency, absent T cells with absent or nonfunctional B cells, absent thymic shadow), X-linked Agammaglobulinemia (Bruton's; BTK mutation, pre-B cell arrest, absent mature B cells and immunoglobulins), and DiGeorge syndrome (22q11.2 microdeletion, thymic and parathyroid aplasia).

Rheumatoid Arthritis (RA) is characterized by high-specificity anti-CCP antibodies, rheumatoid factor (IgM anti-Fc of IgG), and proliferative synovial pannus causing symmetric erosive MTP polyarthritis, hallux valgus, fibular deviation of lesser digits, and cock-up toe deformities.

HLA-B27 seronegative spondyloarthropathies lack rheumatoid factor and feature prominent lower extremity enthesitis; Reactive Arthritis (Reiter syndrome) presents following Chlamydia or enteric dysentery with the triad of urethritis, conjunctivitis, and arthritis, along with characteristic keratoderma blennorrhagica on the soles.

Last updated: October 2026

6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity

Independent study guide by ExamFinch.

Core Examination Pearl: Board examiners heavily test the four Gell-Coombs hypersensitivity reaction types with their clinical prototypes, the clinical pharmacology of local anesthetic allergies (esters vs. amides and the role of PABA and methylparaben), the classical pediatric immunodeficiencies (SCID, Bruton's, DiGeorge), and the podiatric manifestations of Rheumatoid Arthritis versus HLA-B27 seronegative spondyloarthropathies (especially Reactive Arthritis and keratoderma blennorrhagica).

1. The Gell & Coombs Classification of Hypersensitivity Reactions

Hypersensitivity reactions represent exaggerated or inappropriate immune responses that result in host tissue destruction and disease. Philip Gell and Robin Coombs classified these reactions into four pathophysiological categories: +-----------------------------------------------------------------------------------------+

  • | THE GELL & COOMBS HYPERSENSITIVITY MATRIX |
  • +-----------+-----------------------+-----------------------------+-----------------------+
  • | Type | Pathophysiologic Mech | Primary Immune Mediators | Clinical Prototypes |
  • +-----------+-----------------------+-----------------------------+-----------------------+
  • | Type I | Immediate / | IgE cross-linking on mast | • Anaphylaxis |
  • | | Anaphylactic | cells; Histamine, LTC4-E4 | • Allergic asthma |
  • | | (Minutes) | PGD2; Eosinophils (IL-5) | • Acute urticaria |
  • +-----------+-----------------------+-----------------------------+-----------------------+
  • | Type II | Cytotoxic / Antibody- | IgG or IgM against tissue | • Goodpasture syn |
  • | | Mediated | antigens; Complement lysis, | • Myasthenia gravis |
  • | | (Hours to days) | ADCC (NK cells), or agonism | • Graves disease |
  • +-----------+-----------------------+-----------------------------+-----------------------+
  • | Type III | Immune Complex- | Soluble antigen-antibody | • Serum sickness |
  • | | Mediated | complexes in vessels; C5a, | • SLE (nephritis) |
  • | | (Hours to days) | neutrophil leukocytoclasia | • Post-strep GN |
  • +-----------+-----------------------+-----------------------------+-----------------------+
  • | Type IV | Delayed-Type (DTH) / | Sensitized CD4+ Th1 (IFN-g, | • PPD skin test |
  • | | Cell-Mediated | macrophages) or CD8+ CTLs; | • Contact dermatitis |
  • | | (24 to 72 hours) | NO antibodies or complement | • Topical antibiotic |
  • +-----------+-----------------------+-----------------------------+-----------------------+
  • 2. Type I (Immediate) Hypersensitivity & Podiatric Anesthetic Allergy
  • Immunological Mechanism

Sensitization Phase: Initial exposure to an allergen drives CD4+ Th2 differentiation. Th2 cells secrete IL-4 and IL-13 , stimulating B-cell class switching to IgE . Secreted IgE binds with extreme affinity to Fc ϵ \epsilon ϵ RI receptors on the surface of tissue mast cells and circulating basophils, priming the cells.

Effector Phase (Re-exposure): Multivalent allergen cross-links membrane-bound IgE-Fc ϵ \epsilon ϵ RI complexes, triggering intracellular phosphorylation cascades that drive:

Immediate Phase (Minutes): Explosive degranulation releasing preformed chemical mediators: Histamine (binds H1 receptors, inducing endothelial cell contraction, rapid vasodilation, and bronchial smooth muscle spasm), Tryptase (serum marker of mast cell activation), and Heparin .

Late Phase (2 to 8 Hours): De novo synthesis and release of arachidonic acid metabolites via 5-lipoxygenase: Leukotrienes LTC 4 \text{LTC}_4 LTC 4 ​ , LTD 4 \text{LTD}_4 LTD 4 ​ , and LTE 4 \text{LTE}_4 LTE 4 ​ (collectively termed slow-reacting substance of anaphylaxis; 1,000 times more potent than histamine in causing prolonged bronchoconstriction and vascular permeability) and Prostaglandin PGD 2 \text{PGD}_2 PGD 2 ​ , alongside cytokines ( TNF- α \alpha α , IL-5 recruiting eosinophils).

Clinical Podiatric Pharmacology: Local Anesthetic Adverse Reactions

In podiatric clinical practice, adverse reactions following local anesthetic infiltration are common, but true IgE-mediated Type I allergic anaphylaxis accounts for less than 1% of all adverse events. The clinician must accurately differentiate true allergic reactions from non-allergic systemic toxicity: +-----------------------------------------------------------------------------------------+

  • | LOCAL ANESTHETIC CLASSES & ALLERGENIC MECHANISMS |
  • +-----------------------+-----------------------------+-----------------------------------+
  • | Chemical Class | Representative Agents | Allergenic & Metabolic Profile |
  • +-----------------------+-----------------------------+-----------------------------------+
  • | **Ester Class** | • Procaine (Novocain) | • Metabolized by plasma |
  • | (Contains one 'i') | • Chloroprocaine (Nesacaine)| pseudocholinesterase to |
  • | | • Tetracaine (Pontocaine) | **Para-Aminobenzoic Acid (PABA)**|
  • | | • Cocaine | • **High potential for Type I & |
  • | | | Type IV allergic reactions** |
  • +-----------------------+-----------------------------+-----------------------------------+
  • | **Amide Class** | • Lidoc**a**ine (Xylocaine) | • Metabolized by hepatic P450 |
  • | (Contains two 'i's) | • Bupiv**a**caine (Marcaine)| • **True allergy extraordinarily |
  • | | • Mepiv**a**caine (Carbocain| rare (<0.1%)** |
  • | | • Ropiv**a**caine (Naropin) | • Reactions usually caused by |
  • | | | **Methylparaben** preservative |
  • +-----------------------+-----------------------------+-----------------------------------+

Important

Preservative vs. Anesthetic Allergy: Multi-dose vials of amide local anesthetics contain the antioxidant preservative methylparaben , which is chemically metabolized to a compound nearly identical to PABA . A patient reporting an "allergy to lidocaine" typically reacted to methylparaben in a multi-dose vial. In such patients, the podiatric surgeon must select a single-dose, preservative-free (MPF - Methylparaben-Free) amino-amide anesthetic (e.g., 1% preservative-free lidocaine or 0.5% preservative-free bupivacaine).

Epinephrine Reactions: Intravascular injection of epinephrine causes transient tachycardia, palpitations, diaphoresis, tremulousness, and hypertension, often misinterpreted by the patient as an "allergy."

Vasovagal Syncope: Neurocardiogenic reaction characterized by bradycardia, hypotension, pallor, and diaphoresis, responding promptly to Trendelenburg positioning.

Local Anesthetic Systemic Toxicity (LAST): Accidental intravascular injection of large anesthetic volumes causes biphasic CNS excitation (perioral numbness, metallic taste, tinnitus, seizures) followed by CNS depression and catastrophic cardiovascular collapse (arrhythmias, refractory asystole; particularly with bupivacaine). Reversible with 20% Intralipid emulsion therapy .

3. Type II (Cytotoxic) Hypersensitivity

Type II hypersensitivity is mediated by IgG or IgM antibodies directed against fixed, endogenous cellular or tissue-specific antigens . Antigen-antibody binding causes pathology via three distinct mechanisms:

Complement-Dependent Cytotoxicity (CDC): Antibodies bind cell-surface antigens and activate the classical complement cascade. C3b deposition leads to opsonization and phagocytosis by splenic macrophages, or terminal assembly of the Membrane Attack Complex (MAC) causes direct osmotic lysis.

Clinical Prototypes: Autoimmune Hemolytic Anemia (AIHA) (warm IgG vs. cold IgM antibodies against RBCs; confirmed via direct Coombs test), Immune Thrombocytopenic Purpura (ITP) (anti-GpIIb/IIIa antibodies), and Acute Hemolytic Transfusion Reactions (ABO incompatibility).

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): IgG antibodies coat target cells. The Fc region of bound IgG is engaged by CD16 (Fc γ \gamma γ RIII) receptors on Natural Killer (NK) cells , neutrophils, and macrophages, triggering the release of perforin and granzymes that induce target cell apoptosis.

Antibody-Mediated Cellular Dysfunction (Receptor Targeting): Autoantibodies bind to functional cell-surface receptors without provoking cell destruction, acting as agonists or antagonists:

Myasthenia Gravis: Autoantibodies against nicotinic acetylcholine receptors (anti-AChR) at the motor endplate competitively block neuromuscular transmission and induce receptor internalization, causing progressive fatigable muscle weakness and ptosis.

Graves Disease: Autoantibodies against the TSH receptor (Thyroid-Stimulating Immunoglobulins / TSI) act as continuous agonists, stimulating autonomous thyroid follicular cell proliferation and hyperthyroidism.

Pemphigus Vulgaris: Autoantibodies directed against desmoglein-1 and desmoglein-3 within epithelial desmosomes cause intraepidermal acantholysis with flaccid, fragile blisters and a positive Nikolsky sign .

Bullous Pemphigoid: Autoantibodies directed against hemidesmosomal proteins ( BP180 and BP230 ) at the dermoepidermal junction provoke subepidermal blister formation with tense bullae and a negative Nikolsky sign .

Goodpasture Syndrome: Autoantibodies against the non-collagenous domain of the α 3 \alpha_3 α 3 ​ chain of Type IV collagen in basement membranes, producing linear immunofluorescence in renal glomeruli (crescentic glomerulonephritis) and pulmonary alveoli (pulmonary hemorrhage).

Acute Rheumatic Fever: Antibodies against group A streptococcal M protein cross-react with human cardiac myosin and sarcolemmal antigens ( molecular mimicry ).

4. Type III (Immune Complex-Mediated) Hypersensitivity

Type III hypersensitivity is initiated when soluble antigen-antibody complexes (typically occurring in slight antigen excess) form in the circulation and fail to be cleared by the mononuclear phagocyte system.

Pathogenesis of Immune Complex Vasculitis

Circulating Deposition: Small, soluble antigen-antibody complexes circulate and deposit within high-pressure filtration microvasculature: the renal glomerular basement membrane, synovial microvessels, and dermal postcapillary venules.

Complement Activation: Deposited complexes activate the classical complement cascade, liberating potent anaphylatoxins C3a and C5a .

Neutrophilic Infiltration & Leukocytoclasia: C5a attracts massive numbers of neutrophils to the vessel wall. Neutrophils attempt to phagocytose the basement membrane-bound complexes ("frustrated phagocytosis"), releasing lysosomal elastases, proteases, and reactive oxygen species that digest the vascular wall. This produces fibrinoid necrosis , microthrombi, and nuclear fragmentation of dying neutrophils ( leukocytoclastic vasculitis ).

Clinical Prototypes of Type III Reactions

Systemic Lupus Erythematosus (SLE): Deposition of DNA-anti-dsDNA complexes in renal glomeruli (lupus nephritis) producing a granular, "lumpy-bumpy" pattern on immunofluorescence.

Post-Streptococcal Glomerulonephritis (PSGN): Nephritogenic streptococcal antigen-antibody complexes deposit in subepithelial humps 1 to 3 weeks after pharyngeal or impetiginous streptococcal infection.

Serum Sickness: A systemic prototype occurring 7 to 14 days following administration of foreign animal serum (e.g., horse antivenom) or chimeric monoclonal antibodies. Manifests with fever, generalized urticaria, polyarthralgia, lymphadenopathy, and hypocomplementemia (low C3/C4).

Arthus Reaction: A localized cutaneous Type III reaction occurring 4 to 12 hours after intradermal injection of an antigen into an individual with high circulating IgG levels (e.g., tetanus-diphtheria booster). Rapid immune complex formation within dermal arterioles causes acute local edema, hemorrhage, and ischemic necrosis.

Polyarteritis Nodosa (PAN): Systemic necrotizing vasculitis of medium-sized muscular arteries; approximately 30% of cases are mediated by chronic Hepatitis B surface antigen-antibody (HBsAg-anti-HBs) complexes.

5. Type IV (Delayed-Type / Cell-Mediated) Hypersensitivity

Type IV hypersensitivity is completely cell-mediated by sensitized T lymphocytes; it is entirely independent of antibodies and complement . Manifestations require 24 to 72 hours to evolve (hence "delayed").

Effector Pathways

CD4+ Th1 DTH (Delayed-Type Hypersensitivity): Sensitized CD4+ memory Th1 cells recognize peptide-MHC II on local APCs and secrete massive quantities of IFN- γ \gamma γ and TNF- α \alpha α . IFN- γ \gamma γ powerfully activates tissue macrophages, inducing their transformation into epithelioid histiocytes and multinucleated Langhans giant cells , driving granuloma formation .

CD8+ CTL Direct Cytotoxicity: Sensitized CD8+ cytotoxic T lymphocytes recognize target cells displaying haptenated or foreign peptides on MHC Class I, executing lethal target cell lysis via perforin-granzyme release and Fas-FasL apoptosis.

Clinical Prototypes in Podiatric Medicine

Tuberculin PPD Skin Test (Mantoux Test): Intradermal injection of purified protein derivative from Mycobacterium tuberculosis . Sensitized Th1 memory cells secrete IFN- γ \gamma γ , attracting macrophages and inducing induration peaked at 48 to 72 hours.

Allergic Contact Dermatitis: Low-molecular-weight lipophilic chemical haptens penetrate the stratum corneum and covalently bind to self-proteins in the skin. Epidermal Langerhans cells internalize the haptenated conjugate and migrate to regional lymph nodes to prime naive T cells. Upon subsequent topical re-exposure, primed effector T cells home to the epidermis, causing spongiosis, microvesiculation, intense pruritus, and erythema within 24 to 48 hours.

Common Triggers: Urushiol (poison ivy/oak), nickel (footwear eyelets, buckles), and topical antimicrobial ointments used routinely in podiatry : Neomycin and Bacitracin . Podiatric surgeons frequently misdiagnose postoperative contact dermatitis from triple antibiotic ointment as an acute surgical site wound infection!

Other Type IV Conditions: Multiple Sclerosis, Type 1 Diabetes Mellitus (CTL-mediated destruction of pancreatic β \beta β -cells), Hashimoto thyroiditis, and acute and chronic cellular organ transplant rejection.

Table 1: Comprehensive Comparison of Gell & Coombs Hypersensitivity Types

  • Feature Type I (Immediate) Type II (Cytotoxic) Type III (Immune Complex) Type IV (Delayed / Cell)
  • Immune Mediator IgE antibodies IgG or IgM antibodies IgG or IgM complexes T Lymphocytes (CD4/CD8)

Target Antigen Soluble environmental allergen Surface cellular or tissue antigen Soluble circulating antigen Tissue antigen or chemical hapten

  • Complement Role Not involved Heavily involved (CDC) Heavily involved (C3a, C5a) Not involved
  • Onset Kinetics Minutes (15–30 min) Hours to days Hours to days (4–10 hours) Delayed (24–72 hours)

Key Effector Cells Mast cells, basophils, eosinophils NK cells, macrophages Neutrophils (leukocytoclasia) Th1 cells, macrophages, CTLs

Histopathology Edema, mast cell degranulation Cell lysis or phagocytosis Fibrinoid necrosis of vessels Perivascular mononuclear cuffing

Podiatric Correlation Local anesthetic allergy (ester/PABA) AIHA, bullous pemphigoid Leukocytoclastic vasculitis Contact dermatitis (neomycin)

6. Congenital Primary Immunodeficiency Disorders +-----------------------------------------------------------------------------------------+

  • | PRIMARY CONGENITAL IMMUNODEFICIENCIES |
  • +-----------------------+-----------------------------+-----------------------------------+
  • | Disorder | Underlying Molecular Defect | Clinical & Immunological Hallmarks|
  • +-----------------------+-----------------------------+-----------------------------------+
  • | **Severe Combined** | • X-linked: **IL2RG** defect| • **Absent T cells AND B cells** |
  • | **Immunodeficiency** | (common gamma chain) | • **Absent thymic shadow** |
  • | **(SCID)** | • Autosomal Recessive: | • Opportunistic PCP, Candida thrus|
  • | | **ADA deficiency** | • Live vaccines contraindicated |
  • +-----------------------+-----------------------------+-----------------------------------+
  • | **X-Linked** | • Mutation in **BTK** | • **Pre-B cell arrest** in marrow |
  • | **Agammaglobulinemia**| (Bruton Tyrosine Kinase) | • **Absent mature B cells** (CD19)|
  • | **(Bruton's / XLA)** | • X-linked recessive | • Undetectable IgG, IgM, IgA |
  • | | | • Encapsulated bacteria after 6 mo|
  • +-----------------------+-----------------------------+-----------------------------------+
  • | **DiGeorge Syndrome** | • **22q11.2 microdeletion** | • **CATCH-22 triad** |
  • | **(Thymic** | • Failure of 3rd & 4th | • **Thymic aplasia** (T-cell def) |
  • | ** Hypoplasia)** | pharyngeal pouches | • **Parathyroid aplasia** (tetany)|
  • | | | • Conotruncal cardiac defects |
  • +-----------------------+-----------------------------+-----------------------------------+
  • 1. Severe Combined Immunodeficiency (SCID)

Pathophysiology: Characterized by profound defects in cellular and humoral immunity with absent functional T cells and secondary B-cell dysfunction.

X-Linked SCID (~50% of cases): Mutation in the IL2RG gene encoding the common γ \gamma γ -chain subunit shared by cytokine receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 . The inability to signal through the IL-7 receptor halts T-cell development in the thymus; absent IL-15 signaling prevents NK-cell maturation.

Autosomal Recessive SCID (~15% of cases): Deficiency of Adenosine Deaminase (ADA) . Lack of ADA results in the intracellular accumulation of toxic deoxyadenosine and dATP , which inhibits ribonucleotide reductase and starves rapidly dividing lymphoblasts of dNTPs, exerting profound, selective lymphotoxicity against immature T and B lymphocytes.

Clinical Presentation: Manifests in the first months of life with failure to thrive, chronic intractable diarrhea, recurrent severe viral infections (CMV, RSV), opportunistic fungal infections ( Pneumocystis jirovecii , oral candidiasis), and disseminated bacterial sepsis. Physical examination reveals absent tonsils and lymph nodes ; chest radiography demonstrates complete absence of the thymic shadow . Live vaccines (e.g., BCG, rotavirus, MMR) are strictly lethal.

2. X-Linked Agammaglobulinemia (XLA / Bruton's Disease)

Pathophysiology: Mutation in the BTK gene on the X chromosome, which encodes Bruton Tyrosine Kinase . BTK is an essential intracellular signaling enzyme downstream of the pre-B cell receptor. Its deficiency arrests B-cell development at the pre-B cell stage within bone marrow; pre-B cells cannot mature into naive B cells or exit the marrow.

Clinical Presentation: Symptoms begin after 6 months of age , coinciding with the physiological catabolism of protective transplacental maternal IgG. Characterized by recurrent, severe, invasive sinopulmonary and skin infections with encapsulated pyogenic bacteria ( Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus ), and persistent enteroviral infections (Echovirus, Coxsackievirus) due to lack of neutralizing secretory antibodies.

Laboratory Hallmarks: Complete absence of circulating mature B cells (CD19+, CD20+) ; normal numbers and function of CD3+ T cells; all immunoglobulin isotypes (IgG, IgM, IgA, IgE) are virtually undetectable . Secondary lymphoid tissues lack germinal centers; tonsils are markedly hypoplastic or absent.

3. DiGeorge Syndrome (22q11.2 Deletion / Thymic Hypoplasia)

Pathophysiology: Microdeletion on chromosome 22q11.2 caused by aberrant neural crest migration and failure of development of the third and fourth pharyngeal pouches .

The CATCH-22 Clinical Manifestations:

C onotruncal cardiac malformations (Tetralogy of Fallot, truncus arteriosus, interrupted aortic arch).

A bnormal facies (micrognathia, low-set ears, hypertelorism, short philtrum).

T hymic hypoplasia / aplasia: Severe deficiency of mature T lymphocytes ( CD3+ T cells ); profound vulnerability to viral, fungal, and opportunistic infections; absent thymic shadow on infant chest X-ray.

C left palate.

H ypocalcemia secondary to parathyroid gland aplasia/hypoplasia : manifests as neonatal tetany, carpopedal spasms, and seizures secondary to undetectable PTH.

  • 7. Autoimmune Connective Tissue Diseases in Podiatric Practice
  • 1. Rheumatoid Arthritis (RA)

Pathogenesis: Chronic systemic autoimmune disease characterized by symmetric, erosive synovitis of peripheral diarthrodial joints. Autoreactive CD4+ Th1 and Th17 cells infiltrate the synovial membrane, stimulating synovial fibroblasts, osteoclasts, and macrophages via TNF- α \alpha α , IL-1 , and IL-6 . This promotes hyperplastic proliferation of the synovium into an invasive, vascularized inflammatory tissue called pannus . The pannus releases matrix metalloproteinases and cathepsins that erode articular cartilage and subchondral bone.

Serologic Diagnostic Markers:

Anti-Cyclic Citrullinated Peptide (anti-CCP / ACPA): Directed against citrullinated filaggrin/vimentin peptides. High sensitivity (~75%) and exceptional specificity (>95–98%) ; correlates with aggressive, erosive joint destruction.

Rheumatoid Factor (RF): An IgM autoantibody directed against the Fc portion of human IgG . Present in ~75–80% of patients; lower specificity than anti-CCP (can be elevated in hepatitis C, SLE, Sjögren syndrome, and endocarditis).

Lower Extremity Podiatric Manifestations:

Symmetrical polyarthritis predilecting the metatarsophalangeal (MTP) joints (earliest sites of foot involvement, especially 2nd through 5th MTPs) and subtalar/talonavicular joints.

Hallux Valgus: Erosive destruction of the medial collateral ligament and first metatarsal head allows lateral deviation of the great toe.

Fibular Deviation of Lesser Toes: MTP joint capsule laxity and extensor digitorum longus pull cause the lesser digits to drift laterally toward the fibular border.

Dorsal MTP Subluxation / Dislocation ("Cock-Up" Toes): Proximal phalanges subluxate dorsally onto metatarsal heads, displacing the protective plantar fat pad distally into the sulcus. The denuded metatarsal heads project directly plantarward into the skin, causing severe, intractable metatarsalgia ("walking on stones or marbles") and painful intractable plantar keratoses (IPKs).

Rheumatoid Nodules: Fibrinoid necrosis surrounded by a palisade of histiocytes, located over pressure points (Achilles tendon, plantar heel).

2. Systemic Lupus Erythematosus (SLE)

Pathogenesis: Type III hypersensitivity disease characterized by loss of immune tolerance to nuclear self-antigens, defective clearance of apoptotic nuclear debris, and deposition of circulating immune complexes in multi-organ vascular beds.

Diagnostic Autoantibodies:

Antinuclear Antibodies (ANA): Screening test with >98% sensitivity , but low specificity.

Anti-double-stranded DNA (anti-dsDNA): High specificity (>95%); serum titers correlate directly with disease flares and the severity of lupus nephritis .

Anti-Smith (anti-Sm): Highly specific for SLE; directed against core proteins of small nuclear ribonucleoproteins (snRNPs); does not correlate with disease activity.

Antiphospholipid Antibodies: (Lupus anticoagulant, anticardiolipin, anti- β 2 \beta_2 β 2 ​ -glycoprotein I). Induce a hypercoagulable state with recurrent deep vein thrombosis (DVT) in the lower extremities, arterial occlusion, and recurrent pregnancy loss.

Lower Extremity Manifestations:

Jaccoud's Arthropathy: Deforming arthropathy of MTP and PIP joints characterized by ulnar/fibular deviation and reducible subluxations without bony erosion on radiographs (distinguishing it from the destructive erosions of RA).

Raynaud Phenomenon: Reversible digital vasospasm induced by cold or stress, producing classic triphasic color changes (white pallor, blue cyanosis, red reactive hyperemia).

Livedo Reticularis: Violaceous, reticulated, net-like vascular mottling of the skin of the lower legs and feet caused by microvascular stasis.

8. HLA-B27 Seronegative Spondyloarthropathies

The seronegative spondyloarthropathies are a unified group of inflammatory joint diseases characterized by strong genetic association with HLA-B27 (MHC Class I allele), absence of Rheumatoid Factor (RF negative / seronegative) , prominent axial spine involvement (sacroiliitis), asymmetric peripheral oligoarthritis, and enthesitis (inflammation at the insertions of ligaments, tendons, or joint capsules into bone):

1. Ankylosing Spondylitis

Predominantly affects young males (HLA-B27 positive in >90% of patients).

Starts with bilateral sacroiliitis, ascending to vertebral syndesmophyte bridging and fusion (" bamboo spine ").

Lower Extremity Hallmarks: Severe, recalcitrant Achilles enthesitis and plantar fasciitis with proliferative calcaneal traction spurs at tendinous insertions.

2. Psoriatic Arthritis (PsA)

Develops in ~15–30% of patients with cutaneous psoriasis.

Clinical Patterns: Involves the Distal Interphalangeal (DIP) joints of toes and fingers (rarely involved in RA), accompanied by psoriatic nail dystrophy ( nail pitting, onycholysis, oil-drop stains ).

Dactylitis ("Sausage Digit"): Uniform, diffuse, painful swelling of an entire digit resulting from concurrent flexor tenosynovitis and joint synovitis.

Radiographic Hallmark: "Pencil-in-Cup" deformity (osteolysis of the head of the proximal phalanx tapering into a pencil shape, which rests within the excavated, expanded cup of the adjacent distal phalanx base).

3. Reactive Arthritis (Reiter Syndrome)

Triggering Infection: Develops 1 to 4 weeks following an antecedent genitourinary infection (most commonly Chlamydia trachomatis ) or gastrointestinal dysentery ( Campylobacter jejuni , Salmonella enterica , Shigella flexneri , Yersinia enterocolitica ).

The Classic Clinical Triad:

  • "Can't see, can't pee, can't climb a tree"
  • Nongonococcal Urethritis / Cervicitis ("Can't pee")
  • Conjunctivitis / Anterior Uveitis ("Can't see")

Asymmetric Oligoarthritis & Enthesitis ("Can't climb a tree") — Predilects the knees, ankles, and MTP joints, with prominent Achilles tendinitis and retrocalcaneal bursitis.

Dermatologic Podiatric Hallmarks:

Keratoderma Blennorrhagica: Pathognomonic hyperkeratotic, crusty, brownish-red pustular plaques and papules on the soles of the feet and palms , clinically and histologically indistinguishable from pustular psoriasis.

Circinate Balanitis: Painless, shallow serpiginous erosions on the glans penis.

Diffuse subungual hyperkeratosis and yellowish nail plate thickening.

Table 2: Rheumatoid Arthritis vs. HLA-B27 Seronegative Spondyloarthropathies

  • Clinical Parameter Rheumatoid Arthritis (RA) Reactive Arthritis (Reiter) Psoriatic Arthritis (PsA)
  • HLA Association HLA-DR4 (MHC Class II) HLA-B27 (MHC Class I) HLA-B27 (MHC Class I)

Autoantibodies RF positive (80%), anti-CCP positive Seronegative (RF/anti-CCP negative) Seronegative (RF/anti-CCP negative)

Joint Symmetry Symmetric bilateral polyarthritis Asymmetric oligoarthritis Asymmetric or symmetric

Primary Joint Sites MCPs, PIPs, MTP joints (DIPs spared) Lower extremity: knees, ankles, MTPs DIP joints of toes/fingers , axial

Enthesitis Infrequent Hallmark (Achilles / Plantar Fascia) Hallmark (Dactylitis / "Sausage Digit")

Radiographic Signs Marginal bony erosions, osteopenia Fluffy periostitis, calcaneal spurs "Pencil-in-cup" deformity , osteolysis

Cutaneous Hallmarks Subcutaneous rheumatoid nodules Keratoderma blennorrhagica on soles Psoriatic plaques, nail pitting, onycholysis

Preceding Infection None Chlamydia or GI dysentery (1–4 wks) None